Lat­est news on Covid boost­ers safe­ty sig­nal; As­traZeneca leads trio of M&A; The biggest news out of #JPM23; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Hel­lo — we know it’s not Sat­ur­day but Mon­day, but since End­points News is tak­ing a break for MLK Day, we thought we’d change up the time this week. Whether you’re re­cov­er­ing from the JP Mor­gan con­fer­ence like me or watched from afar, this edi­tion of the End­points Week­ly has got you cov­ered on every­thing you need to know from last week. I was thrilled to meet some of you in San Fran­cis­co and learned so much from con­ver­sa­tions, for­mal or in­for­mal. It’s been more than three years since I’ve stepped foot in the US (or left Asia!), so the trip was ex­tra spe­cial.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN